B · Normal
[Simcere Pharmaceuticals: The new drug marketing application of zapxitinib for the treatment of rheumatoid arthritis has been accepted by the State Food and Drug Administration] On November 6, Simcere Pharmaceuticals announced on November 6 that the new drug marketing application of zapxitinib, a highly selective second-generation JAK1 inhibitor in cooperation with Lingke Pharmaceutical (Zhejiang) Co., Ltd., for the treatment of moderately to severe active rheumatoid arthritis, has been officially accepted by the Drug Evaluation Center of the State Food and Drug Administration. This is also the second indication for zeptoxitinib to enter the registration review stage in China.
Comments